Our findings have potential clinical significance for developing monoclonal antibodies to block VEGF-D in cancer and for optimizing protein growth factors to promote therapeutic lymphangiogenesis and lymphatic remodeling to treat lymphedema and inflammatory conditions. This evidence concerns the gene VEGFD and cancer.